Related Experiment Video
Updated: Aug 6, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Safety and clinical outcomes of transarterial microembolization for accessory navicular syndrome refractory to
Takatoshi Kubo1, Ahmed Farhan2, Masahiko Shibuya3
1Department of Interventional Radiology, Okuno Clinic Tokyo, 4th Floor Ginrei Building, 7-8-4, Roppongi, Minato-Ku, Tokyo 106-0032, Japan; Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Background:
Transarterial microembolization (TAME) relieves pain by embolizing inflammatory neovessels. As inflammation is a key driver of pain in accessory navicular syndrome (ANS), TAME may be a therapeutic option for patients refractory to conservative management.
Methods:
We retrospectively analyzed 75 patients (36 females; mean age, 23 ± 15 years) with refractory ANS treated with TAME (Sep 2020-Aug 2024). Adverse events were recorded. Outcomes were assessed using Numeric Rating Scale (NRS) and European Foot and Ankle Society (EFAS) scores.
Results:
No major complications were observed. Mean NRS improved from 6.9 ± 1.5 at baseline to 1.6 ± 2.1 at 12 months and 1.4 ± 1.9 at final assessment (mean 31 ± 13 months) (p < 0.001). Mean EFAS scores increased from 7.6 ± 5.1-18.8 ± 6.0 at 12 months and 20.3 ± 5.5 finally (p < 0.001).
Conclusions:
TAME demonstrated a favorable safety profile and provided durable symptomatic relief for ANS.
Level Of Evidence:
IV.
